Abstract: A method of analyzing protein-protein interactions includes binding the first proteins to the substrate where the first proteins are tagged with the first markers which bind specifically to the biomolecules immobilized on the substrate or the first proteins bind specifically to the biomolecules immobilized on the substrate; incubating the substrate bound first proteins with cell lysate containing the second proteins which are tagged with second markers; analyzing the interactions between the first proteins and the second proteins in the cell lysate, and obtaining the first analytic value representing the kinetic picture of the interactions; incubating the substrate bound first proteins with cell lysate mixture of a cell lysate consisting of the second markers-tagged second proteins and another cell lysate comprising other proteins including unlabelled second proteins and obtaining the second analytic value; comparing and analyzing the first and the second analytic values.
Type:
Grant
Filed:
July 6, 2017
Date of Patent:
May 8, 2018
Assignee:
KOREA ADVANCED INSTITUTE OF SCIENCE AND TECHNOLOGY
Abstract: A method of capturing a sperm deoxyribo nucleic acid (DNA) in a sample is disclosed. The method includes a step of contacting a lysis solution to the sample that includes at least a sperm cell or a sperm cell lysate to lyse the sperm cell. The sperm cell or sperm cell lysate includes a protamine-DNA complex. The method further includes applying at least a protamine-specific antibody to the lysed sperm cell, wherein the protamine-specific antibody binds to the protamine-DNA complex of the lysed sperm cell to form an antibody-protamine-DNA complex. The method further includes capturing the antibody-protamine-DNA complex; and isolating and detecting the sperm DNA from the captured antibody-protamine-DNA complex.
Type:
Grant
Filed:
March 30, 2015
Date of Patent:
May 1, 2018
Assignee:
GENERAL ELECTRIC COMPANY
Inventors:
Michael John Gerdes, John Richard Nelson, Patrick McCoy Spooner, Ralf Lenigk
Abstract: A detection device and associated systems and methods for detecting analytes from a multiplex reaction are described. In particular, a device for conducting at least one detection reaction using a modified ELISA method including a surface with a detection region and a reference region, a detection sensor, and a light source. The detection device may include a complementary metal-oxide-semiconductor (CMOS) image sensor. The device may be used to measure and report discrete quantities or combinations of discrete analytes, providing information to aid in the prognosis and/or diagnosis of altered states of health in vertebrates.
Abstract: The invention provides methods and devices for isolating chromatin from liquid samples. The devices have a rigid porous matrix on which a ligand is immobilized, with the ligand binding to a protein associated with the chromatin.
Type:
Grant
Filed:
October 20, 2016
Date of Patent:
April 24, 2018
Assignee:
Porvair Filtration Group Limited
Inventors:
Igor Chernukhin, Elena Klenova, David Cowieson, Samantha Brown
Abstract: Methods, compositions, and kits for determining whether a subject has non-alcoholic fatty liver disease (NAFLD) are provided. Methods, compositions, and kits for determining whether a subject has non-alcoholic steatosis are also provided. Methods, compositions, and kits for determining whether a subject has non-alcoholic steatohepatitis (NASH) are also provided.
Type:
Grant
Filed:
February 16, 2017
Date of Patent:
April 17, 2018
Assignee:
SomaLogic, Inc.
Inventors:
Malti Nikrad, Stuart G. Field, Stephen Alaric Williams
Abstract: The present disclosure provides immunoassays using one or more over-labeled fluorescent probes, which provides for rapid, accurate and quantitative detection of one or more target analytes in sample, reading fluorescent intensity. The disclosed immunoassays provide multiplexing capability with low cross-reactivity.
Abstract: The invention provides biomarkers and combinations of biomarkers useful in diagnosing lung diseases such as non-small cell lung cancer or reactive airway disease. The invention also provides methods of differentiating lung disease, methods of monitoring therapy, and methods of predicting a subject's response to therapeutic intervention based on the extent of expression of the biomarkers and combinations of biomarkers. Kits comprising agents for detecting the biomarkers and combination of biomarkers are also provided.
Type:
Grant
Filed:
March 12, 2010
Date of Patent:
April 3, 2018
Assignee:
Cancer Prevention and Cure, LTD.
Inventors:
Sung H Baek, Robert T. Streeper, Elzbieta Izbicka
Abstract: A method for the diagnosis, prognosis and therapeutic monitoring of muscular dystrophy, by detecting titin or one or more fragments of titin in a bodily fluid is provided.
Abstract: A system and method for capturing and analyzing cells comprising: a fluid delivery module; a reservoir configured to receive a biological sample including a target cell population and at least one fluid from the fluid delivery module; a manifold configured to receive and distribute the biological sample and at least one fluid from the reservoir into a cell capture device; a waste chamber configured to couple to the manifold; and a pump configured to couple to the waste chamber. In embodiments of the system configured to promote further purification of captured cells, the system can further comprise a magnet that enables further separation of captured cells from undesired sample materials. The system can additionally further comprise a heater configured to heat at least one fluid and/or biological sample, and a cell capture device configured to couple to the manifold, in order to facilitate capture of the target cell population.
Type:
Grant
Filed:
September 29, 2017
Date of Patent:
March 27, 2018
Assignee:
DeNovo Sciecnes, Inc.
Inventors:
Kalyan Handique, Kyle Gleason, Austin Payne, Priyadarshini Gogoi, Saedeh Sepehri Javdani, Christopher Siemer, Yi Zhou
Abstract: The present application relates to a method for detecting ligand using a biosensor applied the FRET (fluorescence resonance energy transfer) phenomenon. More particularly, the method may be used for simply detecting a ligand in a sample by measuring the FRET of a biosensor under the conditions in which a specific critical temperature is maintained. The method may use a phenomenon in which a ligand-binding protein in a biosensor shows reversible unfolding at a temperature higher than the specific critical temperature and the level of the unfolding changes depending on the concentration of a ligand. The method can be widely applied to a variety of kinds of FRET biosensors using the ligand-binding protein.
Type:
Grant
Filed:
April 27, 2010
Date of Patent:
March 20, 2018
Assignee:
KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY
Inventors:
Seung Goo Lee, Jae Seok Ha, Jae Jun Song
Abstract: Provided are methods for determining level of bioactive testosterone in a biological sample. In one aspect, aromatase enzyme is utilized to convert free, bio-available testosterone into estradiol and the amount of estradiol is measured before and after the addition of enzyme. The difference in measurements provides the amount of bioactive testosterone in the sample. In another aspect, a competitor of testosterone binding to SHBG is utilized to displace testosterone bound to SHBG. Measurements of total testosterone in the sample before addition of competitor and afterwards are taken, such that the delta reflects the amount of testosterone that was bound on SHBG.
Abstract: A method for detecting a site which can be modified with an N-linked glycan chain and to which an N-linked glycan chain is actually linked in a glycoprotein; and a method for determining the state of an N-linked glycan chain addition at the site are provided. A glycoprotein having an N-linked glycan chain linked thereto is subjected to an N-linked glycan chain removal treatment with a peptide N-glycanase, subsequently a site capable of being modified with an N-linked glycan chain, in which an Asn residue has been changed to an Asp residue by the action of the peptide N-glycanase, is treated with an endo-type peptidase capable of recognizing an Asp residue to thereby produce peptide fragments, and subsequently the mass of the fragments is detected. In this manner, a site which can be modified with an N-linked glycan chain and to which an N-linked glycan chain is actually linked can be detected.
Abstract: [Problem] To provide a so-called competitive immunological assay method capable of more uniformly immobilizing on a solid phase a substance equivalent to an antigen. [Solution] This immunological assay method measures an analyte substance in a sample by using: an equivalent substance immobilized on the solid phase during the execution of the assay, the equivalent substance being immunologically equivalent to the analyte substance; and a labeled antibody for specifically binding to the substance equivalent to the analyte substance. The assay method is characterized in that the equivalent substance is immobilized on the solid phase using: a bond between the equivalent substance and a carrier substance, the carrier substance being a substance to which the labeled antibody does not bind; and a bond between the carrier substance and a specific binding substance immobilized on the solid phase, the specific binding substance being a substance that binds specifically to the carrier substance.
Abstract: A method of bioassay for the quantification of peptide fragments comprising a neo-epitope formed by cleavage of mimecan, a protein of an atherosclerotic plaque, by a proteinase is provided. In the method a sample, such as urine or serum, is contacted with an antibody reactive with the neo-epitope and the level of binding of the antibody to peptide fragments in the sample is determined. The assay is predictive of risk of cardiovascular disease events.
Abstract: The present invention provides methods of evaluating a glycoprotein preparation for the absence, presence or amount of an N-acetylhexosamine glycan, e.g., an N-acetylglucosamine glycan.
Type:
Grant
Filed:
September 9, 2015
Date of Patent:
February 13, 2018
Assignee:
MOMENTA PHARMACEUTICALS, INC.
Inventors:
Nathaniel Washburn, Enrique Arevalo, Kevin Millea, Carlos J. Bosques, Jay Duffner, Brian Edward Collins
Abstract: A method of bioassay for the quantification of biomarkers useful in the diagnosis of fibrosis disease and prognosis of its development, including biomarkers indicative of the risk of developing fibrosis after a chronic injury is provided. In particular, according to the present invention, biomarkers relating to degradation fragments of Collagen type I, III, IV, V, and VI, elastin, C-reactive protein, and proteoglycans including Biglycan, Decorin, Versican, and Perlecan are found to be useful.
Type:
Grant
Filed:
March 1, 2017
Date of Patent:
January 30, 2018
Assignee:
Nordic Bioscience A/S
Inventors:
Sanne S. Veidal, Morten A. Karsdal, Diana J. Oersnes-Leeming, Natasha Barascuk Michaelsen, Helene Skjot-Arkil, Antonio Segovia-Silvestre, Efstathios Vassiliadis
Abstract: Disclosed herein are methods and systems for detecting two different epitopes in the same sample using immunohistochemical methods using primary antibodies from the same host species and secondary antibodies immunoreactive with antibodies of the host species of the primary antibodies. Methods to denature and block the first primary antibody contacted with the sample are provided.
Type:
Grant
Filed:
May 2, 2017
Date of Patent:
January 23, 2018
Assignee:
Ventana Medical Systems, Inc.
Inventors:
Jacquelyn Smith, Harry James Hnatyszyn, Erik Olson, Noah Theiss, Alton Yates, Eric Kaldjian, Bharathi Vennapusa
Abstract: Provided herein are compositions and methods for the assembly of a bioluminescent complex from two or more non-luminescent (e.g., substantially non-luminescent) peptide and/or polypeptide units. In particular, bioluminescent activity is conferred upon a non-luminescent polypeptide via structural complementation with another, complementary non-luminescent peptide.
Type:
Grant
Filed:
March 17, 2016
Date of Patent:
January 16, 2018
Assignee:
Promega Corporation
Inventors:
Andrew S. Dixon, Lance Encell, Mary Hall, Keith Wood, Monika Wood, Marie Schwinn, Brock F. Binkowski, Hicham Zegzouti, Nidhi Nath, Subhanjan Mondal, Said Goueli, Poncho Meisenheimer, Thomas Kirkland, James Unch, Dileep K. Pulukkunat, Matthew Robers, Melanie Dart, Thomas Machleidt
Abstract: The present invention provides systems, methods, screens, reagents and kits for optical system analysis of cells to rapidly determine the distribution, environment, or activity of fluorescently labeled reporter molecules in cells for the purpose of screening large numbers of compounds for those that specifically affect neurite outgrowth.